Lu AF87908
Alternative Names: Lu-AF87908Latest Information Update: 28 Nov 2024
At a glance
- Originator Lundbeck A/S
- Class Antidementias; Monoclonal antibodies
- Mechanism of Action Tau protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Alzheimer's disease
Most Recent Events
- 28 Nov 2024 No recent reports of development identified for phase-I development in Alzheimer's-disease in USA (IV, Infusion)
- 28 Nov 2024 No recent reports of development identified for phase-I development in Alzheimer's-disease(In volunteers) in USA (IV, Infusion)
- 19 Jul 2023 Lundbeck completes a phase I clinical trial in Alzheimer's disease in USA (IV) (NCT04149860)